Compare Sprott Uranium Miners ETF (URNM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sprott Uranium Miners ETF vs Zimmer Biomet Holdings Inc — how do they compare? Sprott Uranium Miners ETF trades at $56.07, while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Zimmer Biomet Holdings Inc pays a 1.01% dividend while Sprott Uranium Miners ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| URNM | ZBH | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $83.99 | $104.26 |
52-Week Low | $47.13 | $79.58 |
Market Cap | — | $18.05B |
Enterprise Value | — | $25.11B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
URNM, the Sprott Uranium Miners ETF, trades at $57.38, up 0.54% on the day, with a neutral technical signal. Key support lies at $57 and resistance at $58. The ETF offers concentrated exposure to uranium miners, benefiting from long-term supply deficits and rising demand driven by nuclear energy adoption for AI power needs. Recent news highlights strong fundamentals, including government funding and tech company reactor deals.
Outlook remains positive due to structural uranium supply shortages and increasing nuclear energy demand, though volatility risks persist from price swings and geopolitical factors. Analyst sentiment is mixed, with some advocating pure-miner exposure for higher upside, while others caution on valuation divergences from spot uranium prices.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
